You are here Home Guidance and resources Celgene Pty Limited Regulatory activities for this sponsor. Listen Print Share Loading... Type Australian Public Assessment Report (AusPAR) (1) (-) Australian Public Assessment Report (AusPAR) (1) Prescription medicine decision summary (2) Prescription medicine decision summary (2) Date 2022 (1) 2022 (1) Search Filters applied:Australian Public Assessment Report (AusPAR)Clear all Sponsor content1 result(s) found, displaying 1 to 1 AusPAR: Zeposia 8 September 2022 Australian Public Assessment Report (AusPAR) AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.
AusPAR: Zeposia 8 September 2022 Australian Public Assessment Report (AusPAR) AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.